XML 76 R69.htm IDEA: XBRL DOCUMENT v3.25.3
Commitments and Contingencies - Additional Information (Detail)
¥ in Millions
 1 Months Ended 9 Months Ended
May 31, 2024
CNY (¥)
Sep. 30, 2025
USD ($)
Sep. 30, 2025
CNY (¥)
Sep. 30, 2024
USD ($)
Sep. 30, 2025
CNY (¥)
Commitments And Contingencies Disclosure [Line Items]          
Purchase of property and equipment   $ 1,046,000   $ 2,380,000  
Property and Equipment          
Commitments And Contingencies Disclosure [Line Items]          
Purchase of property and equipment   4,600,000      
Research and Development          
Commitments And Contingencies Disclosure [Line Items]          
Committed to allocate   $ 24,700,000      
Etorel IP Rights          
Commitments And Contingencies Disclosure [Line Items]          
Contingent royalty minimum payment | ¥ ¥ 35.0        
Contingent royalty payment description   For each of the first two years starting from June 2025, the minimum annual commission is RMB 10 million, or approximately $1.4 million, based on the September 30, 2025 spot exchange rate, which has already been included in the IP cost. If the sales-based commission calculated at 5% of annual sales in the first year exceeds RMB 10 million (approximately $1.4 million, based on the September 30, 2025 spot exchange rate) or the commission calculated at 4% of annual sales in the second year exceeds RMB 10 million (approximately $1.4 million, based on the September 30, 2025 spot exchange rate), the excess amount for each year will be recognized as contingent consideration. For the third year through the eighth year, the contingent payments will be calculated at 3%, 2%, 2%, 1%, 1%, and 1% of sales in each year, respectively. For each of the first two years starting from June 2025, the minimum annual commission is RMB 10 million, or approximately $1.4 million, based on the September 30, 2025 spot exchange rate, which has already been included in the IP cost. If the sales-based commission calculated at 5% of annual sales in the first year exceeds RMB 10 million (approximately $1.4 million, based on the September 30, 2025 spot exchange rate) or the commission calculated at 4% of annual sales in the second year exceeds RMB 10 million (approximately $1.4 million, based on the September 30, 2025 spot exchange rate), the excess amount for each year will be recognized as contingent consideration. For the third year through the eighth year, the contingent payments will be calculated at 3%, 2%, 2%, 1%, 1%, and 1% of sales in each year, respectively.    
Contingent royalty payment sales for first year | ¥     ¥ 10.0    
Contingent royalty payment sales for second year | ¥     10.0    
Contingent royalty payment sales spot exchange rate for first year   $ 1,400,000      
Contingent royalty payment sales spot exchange rate for second year   $ 1,400,000      
Contingent royalty payment percentage of sale for first year   5.00%     5.00%
Contingent royalty payment percentage of sale for second year   4.00%     4.00%
Contingent royalty payments percentage of sale for third year   3.00%     3.00%
Contingent royalty payments percentage of sale for fourth year   2.00%     2.00%
Contingent royalty payments percentage of sale for fifth year   2.00%     2.00%
Contingent royalty payments percentage of sale for sixth year   1.00%     1.00%
Contingent royalty payments percentage of sale for seventh year   1.00%     1.00%
Contingent royalty payments percentage of sale for eighth year   1.00%     1.00%
Minimum payments based on spot exchange rate   $ 4,900,000      
Minimum annual commission for first two year | ¥     ¥ 10.0    
Minimum annual commission sales spot exchange rate for first two year   1,400,000      
Annual sales commission for first two years exceeding amount | ¥         ¥ 10.0
Annual sales commission spot exchange rate for first two years exceeding amount   $ 1,400,000      
Hydronidone          
Commitments And Contingencies Disclosure [Line Items]          
Contingent royalty payment percentage of sale for first year   10.00%     10.00%
Contingent royalty payment percentage of sale for second year   14.00%     14.00%
Contingent royalty payments percentage of sale for third year   16.00%     16.00%
Contingent royalty payments percentage of sale for fourth year   16.00%     16.00%
Contingent royalty payments percentage of sale for fifth year   16.00%     16.00%
Contingent royalty payments percentage of sale for sixth year   16.00%     16.00%
Contingent royalty payments percentage of sale for seventh year   16.00%     16.00%
Contingent royalty payments percentage of sale for eighth year   15.00%     15.00%
Contingent royalty payments percentage of sale for ninth year   14.00%     14.00%
Contingent royalty payments percentage of sale for tenth year   12.00%     12.00%
Contingent royalty payments percentage of sale for eleventh year   10.00%     10.00%
Contingent royalty payment percentage of sale for twelfth year   8.00%     8.00%
Hydronidone | GNI          
Commitments And Contingencies Disclosure [Line Items]          
Committed to allocate   $ 12,900,000      
Hydronidone | Gyre Pharmaceuticals          
Commitments And Contingencies Disclosure [Line Items]          
Payments for exchange of intellectual property rights   0      
Hydronidone | Gyre Pharmaceuticals | Submission of the New Drug Application          
Commitments And Contingencies Disclosure [Line Items]          
Obligation to pay in exchange for the intellectual property rights   4,700,000     ¥ 33.1
Hydronidone | Gyre Pharmaceuticals | NDA Passes the NMPA's Review and Inspection          
Commitments And Contingencies Disclosure [Line Items]          
Obligation to pay in exchange for the intellectual property rights   1,200,000     8.3
Hydronidone | Gyre Pharmaceuticals | NMPA's Approval of the NDA          
Commitments And Contingencies Disclosure [Line Items]          
Obligation to pay in exchange for the intellectual property rights   $ 7,000,000     ¥ 49.6